These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22217666)

  • 21. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
    Korshunov A; Meyer J; Capper D; Christians A; Remke M; Witt H; Pfister S; von Deimling A; Hartmann C
    Acta Neuropathol; 2009 Sep; 118(3):401-5. PubMed ID: 19543740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
    Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
    Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Clinical, Tumor, and Treatment Characteristics With Seizure Control in Patients With
    Bruno F; Pellerino A; Conti Nibali M; Pronello E; Cofano F; Rossi M; Levis M; Bertero L; Soffietti R; Cassoni P; Garbossa D; Bello L; Rudà R
    Neurology; 2024 May; 102(10):e209352. PubMed ID: 38684041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.
    Liu XY; Gerges N; Korshunov A; Sabha N; Khuong-Quang DA; Fontebasso AM; Fleming A; Hadjadj D; Schwartzentruber J; Majewski J; Dong Z; Siegel P; Albrecht S; Croul S; Jones DT; Kool M; Tonjes M; Reifenberger G; Faury D; Zadeh G; Pfister S; Jabado N
    Acta Neuropathol; 2012 Nov; 124(5):615-25. PubMed ID: 22886134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimation of the occurrence rates of
    Cho U; Yang SH; Yoo C
    J Int Med Res; 2021 Jun; 49(6):3000605211019258. PubMed ID: 34162262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IDH1/2 mutation is associated with seizure as an initial symptom in low-grade glioma: A report of 311 Chinese adult glioma patients.
    Zhong Z; Wang Z; Wang Y; You G; Jiang T
    Epilepsy Res; 2015 Jan; 109():100-5. PubMed ID: 25524848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
    Capper D; Weissert S; Balss J; Habel A; Meyer J; Jäger D; Ackermann U; Tessmer C; Korshunov A; Zentgraf H; Hartmann C; von Deimling A
    Brain Pathol; 2010 Jan; 20(1):245-54. PubMed ID: 19903171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing.
    Felsberg J; Wolter M; Seul H; Friedensdorf B; Göppert M; Sabel MC; Reifenberger G
    Acta Neuropathol; 2010 Apr; 119(4):501-7. PubMed ID: 20131059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
    Yang Y; Mao Q; Wang X; Liu Y; Mao Y; Zhou Q; Luo J
    J Clin Neurosci; 2016 Sep; 31():56-62. PubMed ID: 27406953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
    Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
    Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hsp27 and its expression pattern in diffusely infiltrating astrocytomas.
    Mäkelä KS; Haapasalo JA; Ilvesaro JM; Parkkila S; Paavonen T; Haapasalo HK
    Histol Histopathol; 2014 Sep; 29(9):1161-8. PubMed ID: 24599602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
    Dubbink HJ; Taal W; van Marion R; Kros JM; van Heuvel I; Bromberg JE; Zonnenberg BA; Zonnenberg CB; Postma TJ; Gijtenbeek JM; Boogerd W; Groenendijk FH; Smitt PA; Dinjens WN; van den Bent MJ
    Neurology; 2009 Nov; 73(21):1792-5. PubMed ID: 19933982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
    Tesileanu CMS; Vallentgoed WR; Sanson M; Taal W; Clement PM; Wick W; Brandes AA; Baurain JF; Chinot OL; Wheeler H; Gill S; Griffin M; Rogers L; Rudà R; Weller M; McBain C; Reijneveld J; Enting RH; Caparrotti F; Lesimple T; Clenton S; Gijtenbeek A; Lim E; de Vos F; Mulholland PJ; Taphoorn MJB; de Heer I; Hoogstrate Y; de Wit M; Boggiani L; Venneker S; Oosting J; Bovée JVMG; Erridge S; Vogelbaum MA; Nowak AK; Mason WP; Kros JM; Wesseling P; Aldape K; Jenkins RB; Dubbink HJ; Baumert B; Golfinopoulos V; Gorlia T; van den Bent M; French PJ
    Acta Neuropathol; 2021 Jun; 141(6):945-957. PubMed ID: 33740099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
    Li J; Zhang H; Wang L; Yang C; Lai H; Zhang W; Chen X; Wang J
    Mol Med Rep; 2015 Sep; 12(3):4376-4381. PubMed ID: 26130305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
    Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
    Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of KIAA1549-BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas.
    Cruz GR; Dias Oliveira I; Moraes L; Del Giudice Paniago M; de Seixas Alves MT; Capellano AM; Saba-Silva N; Cavalheiro S; Cerutti JM; Toledo SR
    J Neurooncol; 2014 Apr; 117(2):235-42. PubMed ID: 24532263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas.
    Lin AL; Rosenblum M; Mellinghoff IK; Tabar VS; Ogilvie S; Schaff L; Yang TJ; Young RJ; Taylor BS; Jonsson P; Bale TA
    Brain Pathol; 2020 May; 30(3):653-660. PubMed ID: 31984581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients.
    Sonoda Y; Kumabe T; Nakamura T; Saito R; Kanamori M; Yamashita Y; Suzuki H; Tominaga T
    Cancer Sci; 2009 Oct; 100(10):1996-8. PubMed ID: 19765000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.
    Ohno M; Narita Y; Miyakita Y; Okita Y; Matsushita Y; Yoshida A; Fukushima S; Ichimura K; Kayama T; Shibui S
    Brain Tumor Pathol; 2012 Oct; 29(4):183-91. PubMed ID: 22790483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
    Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
    World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.